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Abstract
Objectives: To determine the efficacy and safety of peri-articular hyaluronic acid injections in chronic lateral
epicondylosis (tennis elbow).
Design: Prospective randomized clinical trial in primary care sport medicine.
Patients: Three hundred and thirty one consecutive competitive racquette sport athletes with chronic (>3 months)
lateral epicondylosis were administered 2 injections (first injection at baseline) into the subcutaneous tissue and
muscle 1 cm. from the lateral epicondyle toward the primary point of pain using a two-dimensional fanning
technique. A second injection was administered 1 week later.
Outcomes measures: Assessments were done at baseline, days 7, 14, 30, 90 and 356. Efficacy measures included
patient’s visual analogue scale (VAS) of pain at rest (0-100 mm) and following assessment of grip strength (0-100
mm). Grip strength was determined using a jamar hydraulic hand dynamometer. Other assessments included
patients’ global assessment of elbow injury (5 point categorical scale; 1 = no disability, 5 = maximal disability),
patients’ assessment of normal function/activity (5 point categorical scale), patients/physician satisfaction
assessment (10 point categorical scale), time to return to pain-free and disability-free sport and adverse events as
per WHO definition. Differences between groups were determined using an intent-to-treat ANOVA.
Results: Average age of the study population was 49 years (± 12 years). One hundred and sixty-five patients were
randomized to the HA and 166 were randomized to the control groups. The change in VAS pain was -6.7 (± 2.0)
for HA vs -1.3 (± 1.5) for control (p < 0.001). The VAS post handgrip was -7.8 (± 1.3) vs +0.3 (± 2.0) (p < 0.001)
which corresponded to a significant improvement in grip of 2.6 kg in the HA vs control groups (p < 0.01).
Statistically significant improvement in patients’ global assessment of elbow injury (p < 0.02), patients’ assessment
of normal function/activity (p < 0.05) and patients/physician satisfaction assessment (p < 0.05) were also observed
favoring the HA group. Time to return to pain-free and disability-free sport was 18 (± 11) days in the HA group but
was not achieved in the control group. VAS changes were maintained in the HA group at each followup while
those in the control significantly declined from baseline. Assessment of patient and physician satisfaction
continued to favor the HA group at subsequent followup.
Conclusion: Peri-articular HA treatment for tennis elbow was significantly better than control in improving pain at
rest and after maximal grip testing. Further, HA treatment was highly satisfactory by patients and physicians and
resulted in better return to pain free sport compared to control.
Background
Chronic tennis elbow or lateral epicondylosis produces
symptoms of pain and functional disability. Typical
treatments include RICE for acute exacerbations as well
as oral or topical NSAIDs, bracing and physical therapy.
However, there is no consensus on treatment while effi-
cacy of existing treatments is poor. Intra-articular hya-
luronic acid (HA) has shown efficacy equivalent to
NSAID in the treatment of osteoarthritis while it’sp e r i -
articular efficacy and safety have recently been reported
for soft tissue use in acute ankle sprain. Hence, many
patients, particularly those who require more rapid
improvement to return to sport or work activity, or
* Correspondence: petrella@uwo.ca
1Dept Medicine, Canadian Centre for Activity and Aging, 801 Commissioners
Road, London, N6C5J1, Canada
Petrella et al. Sports Medicine, Arthroscopy, Rehabilitation, Therapy & Technology 2010, 2:4
http://www.smarttjournal.com/content/2/1/4
© 2010 Petrella et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.those in whom previous therapies have not achieved
expected results, would benefit from a more rapid alle-
viation of symptoms, while still achieving the longer
term benefits of hyaluronic acid that have been reported
in other soft tissue indications.
Previous studies regarding treatment of chronic tennis
elbow have shown lack of consensus as well as variable
efficacy and high incidence of adverse effects [1]. Hya-
luronic acid has been used in soft tissue application for
acute ankle sprain with high degree of efficacy and very
limited side effect. Hence, given the biocompatibility of
HA in treatment of acute ankle sprain we may show
efficacy in terms of pain and function with low inci-
dence of side effect and treatment of chronic tennis
elbow.
Tennis elbow (lateral epicondylosis), a common cause
of chronic elbow pain and wrist extensor dysfunction in
adults, affects 1-3% of the general population each year
[2]. Tennis players have been reported to account for 5-
8% of all cases, although between 40-50% of all tennis
players will be afflicted with the condition at some time
[3]. Lateral epicondylosis is most prevalent in the fourth
decade of life and the syndrome is rarely seen in indivi-
duals under the age of 30. Localized tenderness around
the lateral epicondyle generally characterizes the condi-
tion, and pain can be reproduced by resisted extension
of the wrist or the middle finger with the elbow in a
straight position. The injury results in elbow pain that
usually heals spontaneously, although it can become a
source of chronic pain and morbidity if left untreated.
On average, a typical episode of lateral epicondylosis
lasts 6-24 months [4]. The primary lesion and epicondy-
losis consists of micro ruptures and result in inflamma-
tory granulation tissue in the tendinous portion of the
origins of the forearm musculature just distal to the epi-
condyle of the humerus. The lesion is found primarily
in the extensor carpi radialis brevis (ECRB) origin, with
less frequent involvement of the extensor carpi radialis
longus (ECRL) and the anterior portion of the extensor
digitorum communis [5]. Nirschl [6] maintains that
angiofibroblastic hyperplasia, resulting from avascular
compromise and subsequent micro tears in the origin of
the ECRB, is the basic cause of chronic lateral epicondy-
losis. While the muscle fibres have adequate blood sup-
ply and good healing potential, the tendon fibres
attached to the periosteum are relatively avascular and
are prone to ischemic stress and thus slow to heal [7].
Recent studies of chronic tennis elbow have not found
any significant evidence of inflammatory processes and
the term epicondylosis has been suggested as a more
appropriate term than epicondylitis [8].
There is currently no consensus on the optimum
treatment, but numerous options are available. The
best available scientific evidence suggests that topical
and possibly oral non-steroidal anti-inflammatory
drugs may be the most useful for short-term pain
relief. Corticosteroid injections may be beneficial as a
temporary measure but carry the risk of possible
adverse affects [9,10]. Symptoms usually start with an
ache in the extensor aspect of the forearm with certain
movements that become localized in the lateral epicon-
dyle. Visible swelling is not a common feature in lat-
eral epicondylosis and, if present, should suggest some
other pathology. Elbow radiographs are usually normal
and seldom helpful. Ectopic calcification of the lateral
epicondyle appears in approximately 25% of the cases
but its presence does not appear to alter prognosis.
Differential diagnosis should include referred pain
from the cervical spine, rheumatoid arthritis, radial
tunnel syndrome and compression of the posterior
interosseous nerve [11].
Hyaluronic acid is a natural occurring biological sub-
stance, which has been shown to have a positive effect
in inter-articular administration for osteoarthritis [12] as
well as more recently periarticular use in acute ankle
sprain [13]. These studies have shown improved pain
and functional range of the arthritic as well as the soft
tissue injury with high degree of patient satisfaction and
few adverse events. Previous studies of topical NSAID
and botulinum toxin for the treatment of epilateral epi-
condylitis [14,15] have shown improved pain at 1-3
months post injection. However, this was associated
with rash, mild gastric upset [14] and digit paresis and
weakness of finger extension [15]. Further, efficacy was
not assessed long term. Hence, given the lack of consen-
sus, the high rate of adverse effects and lack of long
term followup with current options, use of HA, which is
relatively free of these adverse effects and has been used
in ankle sprain with long term efficacy [16], could prove
to be an option for patients with chronic tennis elbow.
Hyaluronic acid is an un-branched, high molecular
weight polysaccharide distributed throughout the body,
especially as a major component of synovial fluid carti-
lage and surrounding structures of arthroidial joints.
The primary role of the HA in these tissues is to main-
tain their visco-elastic structural and functional charac-
teristics. Given the long term efficacy and safety of
periarticular HA in acute ankle sprain, it would suggest
similar protective effects of HA in chronic lateral
epicondylosis.
We are unaware of any other published studies that
have prospectively followed patients who were adminis-
tered HA in lateral epicondylosis for treatment of tennis
elbow in clinical practice.
Hence, we hypothesized that HA administered in the
soft tissue of lateral epicondylosis for chronic tennis
elbow will be well-tolerated with few adverse events and
result in improved clinical pain and function outcomes
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patients administered placebo.
Methodology
We collected data on 331 consecutive patients adminis-
tered HA (a clear solution of sterile 1% sodium hyaluro-
nate in a phosphate buffered saline contained in a
prefilled syringe; 1.2 cc) [165 patients] versus 166
patients administered 1.2 cc saline placebo. Treatment
course was randomized and consisted of 2 injections (1
at baseline and a second at 7 days). Injections were
administered using blinded syringes affixed to a 27-
gauge, 1-inch needle. Skin was prepped using betadine
1%. Injections were delivered by the study physician
using a standard approach along the lateral epicondyle
with the affected arm flexed and resting on a firm sur-
face. Injections were be administered into the soft tissue
1 cm from the lateral epicondyle at the point of greatest
pain in two planes using a fanning technique [13] (Fig.
1) whereby contents were injected on withdrawl of the
needle from the point of maximal tenderness in a single
puncture. All patients had radiograph to exclude other
pathologies at the discretion of the study physician (ie
to exclude fracture). None took any other treatment
modalities during the observation period or 48 hours
prior to assessments. Assessments included general
demographics, comorbidities and previous treatments.
Patients rated pain on a 10 cm VAS, with 0 representing
no pain and 10 representing maximal pain. Patients’ glo-
bal assessment of elbow injury (5 point categorical scale;
1 = no disability, 5 = maximal disability), patients’
assessment of normal function/activity (5 point categori-
cal scale; 1 = no change in function/activity, 5 = maxi-
mal change in normal function/activity) and physician’s
global assessment of elbow injury (5 point categorical
scale; 1 = no impact of injury on function, 5 = maximal
impact of injury on function) were also collected. Global
assessments have not been validated but have been used
previously by our and other groups to link the findings
to implementation into routine practice. Time to return
to pain and disability-free sport and adverse events were
determined from review of a patient diary. After enroll-
ment, patients were randomized (1:1) to one of two
treatments using a computer-generated randomization
schedule: HA or placebo.
Follow-up examinations were completed at Day 14 (±
2 days), Day 30 (± 2 days), Day 90 (± 2 days) and at
Day 356 (± 7 days). Patients will assess pain on a VAS
at rest and after assessment of grip strength. Grip
strength will be determined using a jamar hydraulic
hand dynamometer (Sammons Preston, Bolingbrook,
Illinois). Assessment will be conducted with the patient’s
elbow fully extended, shoulder in neutral position and
the dynamometer’s handle in the middle position.
Patients will perform three grip tests on the affected
arm with a mean score calculated and used for analysis.
During the study, including the follow-up period, the
patients received usual care including RICE (rest, ice,
compression and elevation). Use of any analgesics was
prohibited and all concomitant medication use was
recorded in the patient’s diary. Specifically, no NSAID,
corticosteroid or topical analgesics were allowed during
the study. ASA at the dose of 325 mg and less for cardi-
ovascular prophylaxis was allowed.
Patients were assessed for pain on a VAS at rest and
after assessment of grip strength. Patients’ global assess-
ment of elbow injury (5 point categorical scale), patients’
assessment of normal function/activity (5 point categori-
cal scale), and physician’s global assessment of elbow
injury (5 point categorical scale) was performed. Also,
patients/physician satisfaction assessment (10 point cate-
gorical scale; 1 = no satisfaction with the procedure, 10
= very high satisfaction with the procedure) and review
of a patient diary for adverse events and return to pain
and disability-free sport was performed.
The primary outcome measures were an improvement
on the VAS-pain at rest in the affected elbow and VAS-
pain immediately following grip strength testing. Sec-
ondary outcome measures included patients’ global
assessment of elbow injury (5 point categorical scale),
patients’ assessment of normal function/activity (5 point
categorical scale), physician’s global assessment of elbow
injury (5 point categorical scale), patients/physician
satisfaction assessment (10 point categorical scale), time
to return to pain and disability-free sport, concomitant
medication use and adverse events.
The patients were recruited and screened in 4 sites
(Canadian Center for Activity and Aging; University of
Western Ontario-Fowler-Kennedy Sport Medicine Cen-
ter; U Waterloo Sport Medicine Center; U Guelph Sport
Medicine Center). Patients eligible for the study were 18
or older, with clinically or radiographic diagnosis of ten-
nis elbow, and who were newly referred to the medical
outpatient clinics at the author’s institution which are
primary sport medicine referral centers serving a popu-
lation of 1.5 million patients. Inclusion criteria were
pain at the lateral side of the elbow that had persisted
more than 3 months and pain at the lateral epicondyle
during resisted dorsiflexion of the wrist with the elbow
in full extension. Exclusion criteria were previous local
injection treatments (ie. corticosteroid injections or acu-
puncture), nerve entrapment or systemic neuromuscular
disorders.
The diagram below provides a description of the over-
all study design (Table 1).
The analyses of the efficacy endpoints used an intent-
to-treat (ITT) population. The ITT population was
patients who received at least 1 injection of double-
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were counted in the group they were randomized to
irrespective of their actual treatment assignment.
Statistical Power and Sample Size
For the primary analysis of the change from baseline in
elbow pain we estimated a sample size of 160 per group
using a 40% difference in resting VAS scores at Day 30
between treatment and control, a potential dropout rate
of 25% and 95% confidence assuming a standard devia-
tion of <10 mm of the mean deviation, an a of 5%, and
a b level of 10%.
Results
Both groups (HA = 165 vs placebo = 166) were similar
for age (49 ± 15 vs 47 ± 11) and gender (55 vs 53%
male) distribution (Table 2). There was also no differ-
ence among groups in the duration of their symptoms
(26 vs 33 months). There were no serious adverse events
reported throughout the study. Three patients (1.8%) in
the HA and 5 patients (4%) in the control reported pain
during injection. No other adverse events were reported.
No subjects withdrew from the study during the treat-
ment phase.
Figure 1 Localization and administration of HA.
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8.4 ± 1.6 cm) for HA and control respectively. VAS pain
at rest and after grip testing was significantly better in
the HA vs control (Table 2) at D 30. This was asso-
ciated with significantly greater grip strength, patient
global satisfaction and assessment of normal elbow
function in the HA group vs control (Table 2). Physician
global assessment of elbow injury was significantly bet-
ter for the HA vs the control (Table 2). These differ-
ences persisted at each follow up assessment (90 and
356 days). Time to return to pain-free and disability-free
sport was 18 (± 11) days in the HA group (in 147
patients; 89% response rate) but was not achieved in any
of the control group patients.
Discussion
There is currently no consensus in the management of
chronic tennis elbow. Several, reviews have included var-
ious therapies targeting local or systemic interventions.
Further, these therapies have not shown ability to
shorten the disability period nor have they shown long
term benefit. In our study, patients who received HA for
lateral epicondylosis (tennis elbow) had significantly
greater improvement in VAS pain at rest and after grip
testing than control that persisted to 356 days followup.
T h et r e a t m e n tw a sh i g h l ys a t i s f a c t o r yt op a t i e n t sa n d
physicians and was associated with very few minor and
transient adverse effects. Given the less than optimal
treatment options for tennis elbow and given the
Table 1 Study Flow Chart
Evaluations Baseline/Day1 Day 7 Day 14 Day 30 Day 90 Day 356 Day
Informed Consent X
Medical History X
Vital Signs and Physical Exam X
X-Ray Evaluation X
Patients VAS of pain at rest X X X X X X
Patients VAS of pain after grip assessment X X X X X X
Patients global assessment of elbow injury X X X X X X
Patients assessment of normal function/activity X X X X X X
Physician’s global assessment of elbow injury X X X X X X
Patients/physician satisfaction assessment X X X X X
Time to return to pain and disability-free sport X X X X
HA or placebo Administration X X
Concomitant Medications X X X X X X
Adverse Events X X X X X
Table 2 Comparison of HA and control baseline, 30, 90 and 356 days followup.
Baseline D30 D90 D356
HA Control HA Control HA Control HA Control
Age (y) 49 ± 15 47 ± 11
Male % 55 53
Duration of symptoms (m) 18 ± 17 22 ± 18
VAS-rest (cm) 8.5 ± 11.1 8.4 ± 1.6 2.2 ± 1.2* 7.1 ± 1.3*@ 2.5 ± 1.4* 6.7 ± 1.5*@ 2.4 ± 1.4* 7.7 ± 1.3*@
VAS-grip (cm) 9.8 ± 1.1 9.6 ± 0.4 2.0 ± 1.5* 9.9 ± 1.3*@ 2.2 ± 1.8* 9.3 ± 1.4*@ 2.9 ± 1.4* 9.1 ± 1.1*@
PGS 0.3 ± 1.1 0.4 ± 1.1 4.6 ± 1.4* 1.6 ± 2.2*@ 4.8 ± 0.6* 1.9 ± 0.3*@ 4.8 ± 0.9* 1.1 ± 1.8*@
Grip (PSI) 49.2 ± 1.1 47.9 ± 0.4 68.0 ± 2.1 45.5 ± 1.1*@ 67.7 ± 3.0* 48.1 ± 2.3*@ 65.7 ± 1.8* 45.6 ± 1.3*@
PANF 1.1 ± 2.1 1.7 ± 2.2 4.4 ± 0.2* 2.6 ± 0.4@ 4.8 ± 0.1* 1.3 ± 0.7*@ 4.6 ± 0.3* 0.9 ± 1.9*@
PGA 1.1 ± 1.0 0.9 ± 1.2 4.3 ± 1.1* 1.8 ± 2.2*@ 4.6 ± 1.1* 2.0 ± 1.7*@ 4.7 ± 0.5* 1.3 ± 0.7*@
AE (N) 3 5
VAS-pain are scored as a 100 mm VAS (0 = no pain; 100 = worse pain ever); grip strength (conducted with the patient’s elbow fully extended and the
dynamometer’s handle in the middle position. Patients will perform three grip tests on the affected arm with a mean score calculated and used for analysis–
measure in kg); PGS is patient global satisfaction using a 5 point categorical scale (0 = not satisfied, 5 = fully satisfied); PANF is patient assessment of normal
function using a 5 point categorical scale (0 = no return to normal function, 5 = full return to normal function); PGA is physician’s global assessment of elbow
injury using a 5 point categorical scale (0 = poor patient elbow function and poor pain management, 5 = normal patient elbow function and normal pain
management); AE are adverse events reported.
* = p < 0.05 (within groups); @ = p < 0.05 (between groups)
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tion, periarticular injection with HA may provide an
alternative for clinicians and their patients.
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